Biotech | December 08, 2025
Freenome strikes SPAC deal to go public in 2026
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
Angelini Ventures has already invested €125 million in 22 startups
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
